Literature DB >> 30605149

Checkpoint inhibitors go viral.

Melanie Senior.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30605149     DOI： 10.1038/nbt.4327

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  10 in total

1.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

Authors:  J Fueyo; C Gomez-Manzano; R Alemany; P S Lee; T J McDonnell; P Mitlianga; Y X Shi; V A Levin; W K Yung; A P Kyritsis
Journal:  Oncogene       Date:  2000-01-06       Impact factor: 9.867

Review 2.  Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Authors:  Leisha A Emens; Paolo A Ascierto; Phillip K Darcy; Sandra Demaria; Alexander M M Eggermont; William L Redmond; Barbara Seliger; Francesco M Marincola
Journal:  Eur J Cancer       Date:  2017-06-15       Impact factor: 9.162

Review 3.  Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.

Authors:  Shashi Gujar; Jonathan G Pol; Youra Kim; Patrick W Lee; Guido Kroemer
Journal:  Trends Immunol       Date:  2017-12-20       Impact factor: 16.687

4.  Pfizer exits neuroscience.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2018-02-01       Impact factor: 84.694

Review 5.  Using immunotherapy to boost the abscopal effect.

Authors:  Wilfred Ngwa; Omoruyi Credit Irabor; Jonathan D Schoenfeld; Jürgen Hesser; Sandra Demaria; Silvia C Formenti
Journal:  Nat Rev Cancer       Date:  2018-02-16       Impact factor: 60.716

6.  Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.

Authors:  Juan Fueyo; Ramon Alemany; Candelaria Gomez-Manzano; Gregory N Fuller; Asadullah Khan; Charles A Conrad; Ta-Jen Liu; Hong Jiang; Michael G Lemoine; Kaori Suzuki; Raymond Sawaya; David T Curiel; W K Alfred Yung; Frederick F Lang
Journal:  J Natl Cancer Inst       Date:  2003-05-07       Impact factor: 13.506

7.  Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Authors:  Padma Sampath; Jun Li; Weizhou Hou; Hannah Chen; David L Bartlett; Steve H Thorne
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

8.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Authors:  Antoni Ribas; Reinhard Dummer; Igor Puzanov; Ari VanderWalde; Robert H I Andtbacka; Olivier Michielin; Anthony J Olszanski; Josep Malvehy; Jonathan Cebon; Eugenio Fernandez; John M Kirkwood; Thomas F Gajewski; Lisa Chen; Kevin S Gorski; Abraham A Anderson; Scott J Diede; Michael E Lassman; Jennifer Gansert; F Stephen Hodi; Georgina V Long
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

9.  Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.

Authors:  Rocio Garcia-Carbonero; Ramon Salazar; Ignacio Duran; Ignacio Osman-Garcia; Luis Paz-Ares; Juan M Bozada; Valentina Boni; Christine Blanc; Len Seymour; John Beadle; Simon Alvis; Brian Champion; Emiliano Calvo; Kerry Fisher
Journal:  J Immunother Cancer       Date:  2017-09-19       Impact factor: 13.751

10.  CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy.

Authors:  Aldo Pourchet; Steven R Fuhrmann; Karsten A Pilones; Sandra Demaria; Alan B Frey; Matthew Mulvey; Ian Mohr
Journal:  EBioMedicine       Date:  2016-01-19       Impact factor: 8.143
  10 in total
  11 in total

Review 1.  Intratumoral Immunotherapy for Early-stage Solid Tumors.

Authors:  Wan Xing Hong; Sarah Haebe; Andrew S Lee; C Benedikt Westphalen; Jeffrey A Norton; Wen Jiang; Ronald Levy
Journal:  Clin Cancer Res       Date:  2020-02-18       Impact factor: 12.531

Review 2.  Oncolytic Viruses for Systemic Administration: Engineering a Whole Different Animal.

Authors:  Svetlana Atasheva; Dmitry M Shayakhmetov
Journal:  Mol Ther       Date:  2021-02-05       Impact factor: 11.454

Review 3.  Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity.

Authors:  Alicia Teijeira Crespo; Stephanie Burnell; Lorenzo Capitani; Rebecca Bayliss; Elise Moses; Georgina H Mason; James A Davies; Andrew J Godkin; Awen M Gallimore; Alan L Parker
Journal:  Immunology       Date:  2021-03-28       Impact factor: 7.215

4.  Systemic cancer therapy with engineered adenovirus that evades innate immunity.

Authors:  Svetlana Atasheva; Corey C Emerson; Jia Yao; Cedrick Young; Phoebe L Stewart; Dmitry M Shayakhmetov
Journal:  Sci Transl Med       Date:  2020-11-25       Impact factor: 19.319

5.  Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors.

Authors:  Iris Scherwitzl; Silvana Opp; Alicia M Hurtado; Christine Pampeno; Cynthia Loomis; Kasthuri Kannan; Minjun Yu; Daniel Meruelo
Journal:  Mol Ther Oncolytics       Date:  2020-05-06       Impact factor: 7.200

6.  Oncolytic virus-derived type I interferon restricts CAR T cell therapy.

Authors:  Laura Evgin; Amanda L Huff; Phonphimon Wongthida; Jill Thompson; Tim Kottke; Jason Tonne; Matthew Schuelke; Katayoun Ayasoufi; Christopher B Driscoll; Kevin G Shim; Pierce Reynolds; Dileep D Monie; Aaron J Johnson; Matt Coffey; Sarah L Young; Gary Archer; John Sampson; Jose Pulido; Luis Sanchez Perez; Richard Vile
Journal:  Nat Commun       Date:  2020-06-24       Impact factor: 14.919

7.  By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.

Authors:  Patricia Kleinpeter; Christelle Remy-Ziller; Eline Winter; Murielle Gantzer; Virginie Nourtier; Juliette Kempf; Julie Hortelano; Doris Schmitt; Huguette Schultz; Michel Geist; Catherine Brua; Chantal Hoffmann; Yasmin Schlesinger; Dominique Villeval; Christine Thioudellet; Philippe Erbs; Johann Foloppe; Nathalie Silvestre; Laetitia Fend; Eric Quemeneur; Jean-Baptiste Marchand
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

Review 8.  Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy.

Authors:  Brendon J Coventry
Journal:  Ther Adv Vaccines Immunother       Date:  2019-08-01

Review 9.  Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.

Authors:  Omeed Moaven; Christopher W Mangieri; John A Stauffer; Panos Z Anastasiadis; Mitesh J Borad
Journal:  JCO Precis Oncol       Date:  2021-04-27

Review 10.  Virus-Receptor Interactions: Structural Insights For Oncolytic Virus Development.

Authors:  Nadishka Jayawardena; Laura N Burga; John T Poirier; Mihnea Bostina
Journal:  Oncolytic Virother       Date:  2019-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.